(American Associates, Ben-Gurion University of the Negev) After a follow-up period of 12 years, the mean cumulative cost increase was 37 percent, including all the injectable anticancer drugs. Annual changes in pricing did not appear to be affected by new supplemental FDA approvals, new off-label indications or new competition.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2zlCB6k
No comments:
Post a Comment